Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection

Hiroyuki Kishimoto, Ryoichi Aki, Yasuo Urata, Michael Bouvet, Masashi Momiyama, Noriaki Tanaka, Toshiyoshi Fujiwara, Robert M. Hoffman

Research output: Contribution to journalArticle

64 Citations (Scopus)


We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, technical problems of removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report that in vivo OBP-401 labeling of tumors with GFP before fluorescence-guided surgery reports cancer recurrence after surgery. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.

Original languageEnglish
Pages (from-to)2737-2741
Number of pages5
JournalCell Cycle
Issue number16
Publication statusPublished - Aug 15 2011



  • Adenovirus
  • Cancer labeling
  • Detection
  • Fluorescence-guided surgery
  • Green fluorescent protein
  • In situ
  • Recurrence

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this